3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Hemangioma
8
Hemangioma, Capillary
7
Melanoma
6
Breast Neoplasms
5
Carcinoma, Hepatocellular
4
Sarcoma
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Hypertension, Portal
3
Hemangiosarcoma
3
Fallopian Tube Neoplasms
3
Urinary Bladder Neoplasms
2
Sarcoma, Kaposi
2
Ovarian Neoplasms
2
Hemangioma, Cavernous, Central Nervous System
2
Colorectal Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ulcer
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Spinal Cord Neoplasms
1
Smoldering Multiple Myeloma
1
Skin Neoplasms
1
Interventions
belzutifan
4
gallium Ga 68 dotatate
3
Everolimus
2
vatalanib
1
tanespimycin
1
spartalizumab
1
palbociclib
1
lenvatinib
1
cabozantinib
1
Vorinostat
1
Sunitinib
1
Ranibizumab
1
Propranolol
1
PT2385
1
Oxygen-15
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Fluorodeoxyglucose F18
1
Bevacizumab
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
von Hippel-Lindau Disease
×
Propranolol
×
Clear all
NCT05424016
2023-12-13
PRO-HEB
Assistance Publique - Hôpitaux de Paris
Phase NA
Recruiting
85 enrolled